R&D
BioNTech’s mRNA Cancer Immunotherapy Misses Its First Goal in a Key Head and Neck Cancer Trial
Adding BNT113 to Keytruda did not delay the cancer’s progression at an interim check. The trial continues to see whether patients live longer — but the result is another reminder of how hard it is to improve on Keytruda.